Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Spikevax (previously COVID-19 Vaccine Moderna) Euroopan unioni - suomi - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Mutaflor 2.5-25x10³x10³x10³ CFU enterokapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

mutaflor 2.5-25x10³x10³x10³ cfu enterokapseli, kova

sabora pharma oy - escherichia coli, strain nissle 1917 - enterokapseli, kova - 2.5-25x10³x10³x10³ cfu - mikro-organismeja sisältävät ripulilääkkeet

Cardisure vet. 3.5 mg/ml oraaliliuos Suomi - suomi - Fimea (Suomen lääkevirasto)

cardisure vet. 3.5 mg/ml oraaliliuos

dechra regulatory b.v. - pimobendan - oraaliliuos - 3.5 mg/ml - pimobendaani

Enrotron vet. 50 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

enrotron vet. 50 mg tabletti

animedica gmbh - enrofloxacin - tabletti - 50 mg - enrofloksasiini

Enrotron vet. 150 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

enrotron vet. 150 mg tabletti

animedica gmbh - enrofloxacin - tabletti - 150 mg - enrofloksasiini

Robinul-Neostigmin 0.5 mg/ml + 2.5 mg/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

robinul-neostigmin 0.5 mg/ml + 2.5 mg/ml injektioneste, liuos

viatris oy - glycopyrronium bromide, neostigmine metilsulfate - injektioneste, liuos - 0.5 mg/ml + 2.5 mg/ml - neostigmiini

Hippozol Vet 400 mg enterorakeet Suomi - suomi - Fimea (Suomen lääkevirasto)

hippozol vet 400 mg enterorakeet

cp-pharma handelsgesellschaft mbh - omeprazole - enterorakeet - 400 mg - omepratsoli

OFTAN STARINE 0.5 mg/ml silmätipat, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

oftan starine 0.5 mg/ml silmätipat, liuos

santen oy - tetrahydrozoline hydrochloride - silmätipat, liuos - 0.5 mg/ml - tetrytsoliini

Gleptosil vet. 200 mg Fe3+/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

gleptosil vet. 200 mg fe3+/ml injektioneste, liuos

ceva santÉ animale - gleptoferron - injektioneste, liuos - 200 mg fe3+/ml - rauta